Ignite Creation Date:
2024-05-05 @ 6:38 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00517361
Status:
TERMINATED
Last Update Posted:
2014-04-15
First Post:
2007-08-14
Brief Title:
Phase II Study of Carboplatin and Bevacizumab Avastin for ER Neg PR Neg and HER2Neu Neg Metastatic Breast Cancer
Sponsor:
University of Chicago
Organization:
University of Chicago
Study Overview
Official Title:
A Phase II Study of Carboplatin and Bevacizumab Avastin Combination Therapy for ER Negative PR Negative and HER2Neu Negative Metastatic Breast Cancer
Status:
TERMINATED
Status Verified Date:
2014-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
This study has been terminated due to poor accrual
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the progression free survival PFS of metastatic ER PR and HER2neu negative breast cancers to the combination of carboplatin and bevacizumab Avastin therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None